OVID News and Press, Ovid Therapeutics Inc. From 07/07/21

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at the L...

There are promising results for OV-935 in patients with Dravet Syndrome, with questionable results in patients with Lennox-Gastaut Syndrome (LGS). Pipeline drug OV-935 shows high revenue potential. The stock is at a good entry price today, but there is high risk with phase 3 clini...

Ovid Therapeutics (OVID) announced that current Chief Business Officer Jeffrey Rona has expanded his role to CFO. Prior to joining Ovid Therapeutics, Jeffrey Rona was the Western region Managing Director for Danforth Advisors, a life science financial strategy consultancy. For further ...

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that current Chief Business Officer Jeffrey Rona has expa...

New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological d...

Ovid Therapeutics (OVID): Q1 GAAP EPS of $2.53 beats by $1.80.Revenue of $208.38M beats by $107.85M.Shares +7% AH.Press Release For further details see: Ovid Therapeutics EPS beats by $1.80, beats on revenue

Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in additional milestone payments, plus tiered double-digit royalties, up to 20%, on sale...

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will participate in a virtual fireside chat at ...

Merck should collaborate with GSK on RSV vaccineMerck (MRK) should collaborate with GlaxoSmithKline (GSK) on the latter's development of a RSV (respiratory syncytial) vaccine as it would be a win-win scenario for both companies, writes Citi analyst Andrew Baum.For Merck, it would provide pote...

NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D.,...